Is It Time to Leave the Care of Physicians Who Refuse to Submit Tissue for Chemosensitivity Testing?

One of my favorite patients personally referred a friend from Northern California. The patient herself had suffered recurrent high-grade serous ovarian cancer requiring splenectomy.
A portion of her tumor was submitted to my laboratory, and we identified a highly effective combination. When her oncologist refused to use this simple FDA approved regimen, the patient took it upon herself and commuted to Southern California to receive therapy. She remains in complete remission one year later.
With this as a backdrop, I looked forward to helping her newly diagnosed 69 y/o friend with a large ovarian mass. We awaited arrival of the tumor sample. Disappointingly, the surgeon refused to send it.
It was only after the surgery that we realized the gravity of the situation. The tumor proved to be a clear-cell carcinoma of the ovary. This rare form of ovarian cancer is demonstrably less sensitive to standard carboplatin plus Taxol with responses in the range of 40% range, much lower than the 80% in high-grade.
In collaboration with investigators across the US, we had previously established a clear cell carcinoma program. The tragic loss of the principal investigator prevented us from accruing more than a few patients but those cases showed that clear cell carcinoma behaves very differently from high grade with sensitivity to completely different drugs.
Our preliminary studies, with the University of Arizona provided response in several clear cell patients after they had failed standard carboplatin plus Taxol.
Unfortunately, we were prevented from offering that benefit to this clear-cell cancer patient as her surgeon, in her wisdom, simply did not comply with the patient’s request. She did not do her job.
Now, the distraught patient confronting ineffective therapy and the certainty of toxicity contacted me for answers. Regrettably I had few. There is limited literature on optimal therapy in clear cell, and as we had shown before, these cancers behave quite differently from their high-grade counterparts.
Now the question arises: What can we do to address patients’ needs?
The answer: We need to convince surgeons who are asked to submit tissue to our CLIA licensed laboratory to do so.
There are over 200,000 practicing surgeons in the US. Patients should be prepared to vote with their feet. While denying a surgeon their bread butter is unfortunate, denying a cancer patient the opportunity to save their life is unacceptable.
I am troubled that this patient must undergo carboplatin plus Taxol, with less than a 40% response rate. She is distraught and fears hair loss, neuropathy, low blood counts, and other side effects. Had her surgeon sent tissue the patient we might have found her to be one the fortunate few for whom carboplatin and Taxol works but instead she might have needed carboplatin plus Doxil, or carboplatin plus gemcitabine. All of which could easily have been tested. Now we will never know.
It is time for patients to stop taking these failures lying down. She lodged a formal complaint and is considering litigation.
How else will doctors and medical centers start taking their cancer patients' needs seriously?



